hotspot -WSS

hotspot

author：knowledge 2025-10-01 20:14:27 - browse：996

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Better Therapeutics data on benefit with GLP

entertainment

WSS

How should state employee insurance handle Wegovy?

There’s no way to know how good AI health technologies are

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

STAT Readout Newsletter: Today in biotech, life science news

European regulators consider appeal over Amylyx ALS drug

Eight reasons why you should get an updated Covid vaccine

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Hepatitis C has a cure — but many Americans still lack access to it

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

23andMe had bad news about my health. I wish a person had delivered it

Trump Jan. 6 attorney John Lauro is ex

Supreme Court strikes down use of affirmative action

Nick Jonas talks about managing diabetes along with his career

BioMarin wins approval for gene therapy to treat hemophilia A

Better Therapeutics data on benefit with GLP

What does generative AI mean for health care? We asked experts

European regulators consider appeal over Amylyx ALS drug

explore

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Female surgeons have lower rates of long

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

NYC plans to house migrants on an island in the East River

Readout LOUD podcast: Merger Mondays, Ozempic panic

In medicine, common shorthands can shortchange care

hotspot

entertainment

knowledge

entertainment